Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 7

1.

Preclinical Characteristics of the Irreversible Pan-HER Kinase Inhibitor Neratinib Compared with Lapatinib: Implications for the Treatment of HER2-Positive and HER2-Mutated Breast Cancer.

Collins DM, Conlon NT, Kannan S, Verma CS, Eli LD, Lalani AS, Crown J.

Cancers (Basel). 2019 May 28;11(6). pii: E737. doi: 10.3390/cancers11060737. Review.

2.

Acquired Resistance to Antibody-Drug Conjugates.

Collins DM, Bossenmaier B, Kollmorgen G, Niederfellner G.

Cancers (Basel). 2019 Mar 20;11(3). pii: E394. doi: 10.3390/cancers11030394. Review.

3.

HER-targeted tyrosine kinase inhibitors enhance response to trastuzumab and pertuzumab in HER2-positive breast cancer.

Canonici A, Ivers L, Conlon NT, Pedersen K, Gaynor N, Browne BC, O'Brien NA, Gullo G, Collins DM, O'Donovan N, Crown J.

Invest New Drugs. 2019 Jun;37(3):441-451. doi: 10.1007/s10637-018-0649-y. Epub 2018 Jul 30.

PMID:
30062574
4.

Innovative Technologies Changing Cancer Treatment.

Charmsaz S, Prencipe M, Kiely M, Pidgeon GP, Collins DM.

Cancers (Basel). 2018 Jun 19;10(6). pii: E208. doi: 10.3390/cancers10060208.

5.

The HSP90 inhibitor NVP-AUY922 inhibits growth of HER2 positive and trastuzumab-resistant breast cancer cells.

Canonici A, Qadir Z, Conlon NT, Collins DM, O'Brien NA, Walsh N, Eustace AJ, O'Donovan N, Crown J.

Invest New Drugs. 2018 Aug;36(4):581-589. doi: 10.1007/s10637-017-0556-7. Epub 2018 Feb 2.

PMID:
29396630
6.

Tyrosine kinase inhibitors as modulators of trastuzumab-mediated antibody-dependent cell-mediated cytotoxicity in breast cancer cell lines.

Collins DM, Gately K, Hughes C, Edwards C, Davies A, Madden SF, O'Byrne KJ, O'Donovan N, Crown J.

Cell Immunol. 2017 Sep;319:35-42. doi: 10.1016/j.cellimm.2017.07.005. Epub 2017 Jul 15.

PMID:
28735814
7.

Modulation of P-gp expression by lapatinib.

Dunne G, Breen L, Collins DM, Roche S, Clynes M, O'Connor R.

Invest New Drugs. 2011 Dec;29(6):1284-93. doi: 10.1007/s10637-010-9482-7. Epub 2010 Jul 6.

PMID:
20607587

Supplemental Content

Loading ...
Support Center